Resveratrol demonstrates a striking biphasic response in stem cell function, with 5μM concentrations enhancing regeneration while 50μM doses significantly inhibiting it. The research identified Smad4 as a key mediator at lower concentrations, with PiwiA expression increasing and stem cell proliferation promoted across both doses. However, high concentrations suppressed the differentiation marker Agat1, blocking proper cellular maturation despite maintained proliferation. This dose-dependent paradox reveals why resveratrol research has yielded conflicting results across studies. The finding challenges the widespread assumption that "more is better" with this popular supplement, suggesting therapeutic windows may be narrower than previously recognized. For the millions consuming resveratrol supplements, this research highlights a critical knowledge gap: optimal dosing remains poorly defined in humans. While the planarian model provides valuable mechanistic insights, the translation to human stem cell biology requires careful consideration of bioavailability and tissue-specific responses. This biphasic pattern may explain why some clinical trials show benefits while others report neutral or negative outcomes, underscoring the need for precision dosing rather than the current one-size-fits-all approach to resveratrol supplementation.